Interleukin-1 Induces Interleukin-6 Production in Peripheral Blood Monocytes
Overview
Affiliations
Interleukin-6 (IL-6), a multifunctional cytokine produced in monocytes, fibroblasts, endothelial cells, and keratinocytes, is induced by a variety of stimulating signals, including lipopolysaccharide (LPS), poly (I), poly (C), IL-1, tumor necrosis factor (TNF), and platelet-derived growth factor. Some of these signals induce IL-6 effectively only in one cell type, and this selectivity of induction may explain selectivity of biologic effects. In the present study, we show that IL-1 beta, previously known to be a potent inducer of IL-6 in fibroblasts, endothelial cells, and keratinocytes, but not in monocytes, is also a potent inducer of IL-6 in peripheral blood monocytes. High level IL-6 activity that could be neutralized by specific antibodies to IL-6 was detected in supernatants of IL-1-stimulated monocytes. Maximal induction required IL-1 concentrations of 10 ng/mL. As judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions, IL-6 species of relative molecular mass of 19 to 26 Kd could be specifically immunoprecipitated from supernatants of IL-1-induced monocytes. Size heterogeneity is a reported feature of IL-6 produced in a variety of cell types, and monocyte-derived IL-6 induced by either IL-1 or LPS displayed similar size heterogeneity. The highly purified recombinant IL-1 beta preparation used contained little, if any, LPS. In addition, monocyte production of IL-6, induced by IL-1 beta, was specifically neutralized by anti-IL-1 beta antibodies, demonstrating that IL-1, rather than a contaminant in the IL-1 preparation, was responsible for IL-6 induction. A number of biologic activities have been ascribed both to IL-1 and IL-6. The finding that IL-1 induced IL-6 in monocytes may help in defining the spectrum of biologic activities of each of these interactive cytokines.
Novel strategies to manage CAR-T cell toxicity.
Mulvey A, Trueb L, Coukos G, Arber C Nat Rev Drug Discov. 2025; .
PMID: 39901030 DOI: 10.1038/s41573-024-01100-5.
Basu S, Gohil K, Singh S, Biswas A, Sarangi T, Palit M Global Spine J. 2024; :21925682241309303.
PMID: 39671472 PMC: 11645678. DOI: 10.1177/21925682241309303.
In Vivo Biocompatibility of sp. PCC 7002-Integrated Scaffolds for Skin Regeneration.
Fuchs B, Mert S, Kuhlmann C, Birt A, Hofmann D, Wiggenhauser P J Funct Biomater. 2024; 15(10).
PMID: 39452593 PMC: 11508603. DOI: 10.3390/jfb15100295.
Inflammasome activation in patients with Kaposi sarcoma herpesvirus-associated diseases.
Lage S, Ramaswami R, Rocco J, Rupert A, Davis D, Lurain K Blood. 2024; 144(14):1496-1507.
PMID: 38941593 PMC: 11474434. DOI: 10.1182/blood.2024024144.
Roring R, Li W, Liu R, Bruno M, Zhang B, Debisarun P iScience. 2024; 27(4):109356.
PMID: 38510149 PMC: 10951896. DOI: 10.1016/j.isci.2024.109356.